Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Donate to our blog

Your support will help Science & Enterprise continue to provide science news for business people and business news for scientists.

Lilly Acquires Migraine Therapy Company in $960M Deal

Drug maker Eli Lilly and Company is acquiring CoLucid Pharmaceuticals, a developer of treatments for migraine pain and associated symptoms. . . . → Read More: Lilly Acquires Migraine Therapy Company in $960M Deal

Univ. Spin-Off Develops Lower Cost 3-D Metal Printing

A spin-off enterprise from University at Buffalo engineering school developed a machine that produces lower-cost aluminum parts with three-dimensional liquid metal printing. . . . → Read More: Univ. Spin-Off Develops Lower Cost 3-D Metal Printing

Ionis Options Cardiac Drugs in $1.5 Billion Deal

Biotechnology company Ionis Pharmaceuticals is providing drug maker Novartis first access to two experimental drugs for controlling proteins that promote cholesterol and triglycerides, which contribute to heart disease. . . . → Read More: Ionis Options Cardiac Drugs in $1.5 Billion Deal

Precision Health Tech Network Expands, Invests $400M

Digital Life Alliance, a consortium of enterprises applying advanced technologies to health and medicine that plans to offer personalized solutions, is expanding to 7 members, as well as iCarbonX, the company that founded the network. . . . → Read More: Precision Health Tech Network Expands, Invests $400M

Smartphone System Shown to Control Blood Glucose Levels

A bionic pancreas system using a smartphone was shown in a clinical trial to control blood glucose levels better than a commercial insulin pump in persons with type 1 diabetes. . . . → Read More: Smartphone System Shown to Control Blood Glucose Levels

Stem Cell Therapy Company Formed, Staked to $225M

A pharmaceutical company and health care venture investor are forming BlueRock Therapeutics, a biotechnology enterprise to design regenerative medicine treatments with stem cells. . . . → Read More: Stem Cell Therapy Company Formed, Staked to $225M

Start-Up Reprogramming Stem Cells to Treat Heart Failure

A new enterprise, spun-off from the Gladstone Institutes in San Francisco, plans to regenerate heart muscle from other cells to treat heart failure. . . . → Read More: Start-Up Reprogramming Stem Cells to Treat Heart Failure

Company Launches to Discover Gut-Brain Therapies

A California Institute of Technology biologist is starting a new enterprise to discover treatments for neurological disorders through pathways originating in the gut. . . . → Read More: Company Launches to Discover Gut-Brain Therapies

Novartis Acquires Sickle-Cell Drug Developer

Drug maker Novartis is acquiring Selexys Pharmaceuticals Corp., a developer of treatments for pain episodes associated with sickle cell disease, for $665 million. . . . → Read More: Novartis Acquires Sickle-Cell Drug Developer

Blood Stem Cell Start-Up Launches, Earns $48.5M Funding

A new enterprise, spun-off from Harvard University stem cell labs, aims to make stem cell transplants from bone marrow safer and more reliable. . . . → Read More: Blood Stem Cell Start-Up Launches, Earns $48.5M Funding